-
1
-
-
0000652834
-
Segmental necrotising glomerulonephritis with antineutrophil antibody: Possible arbovirus aetiology?
-
Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J 1982; 285 : 606.
-
(1982)
Br Med J
, vol.285
, pp. 606
-
-
Davies, D.J.1
Moran, J.E.2
Niall, J.F.3
Ryan, G.B.4
-
2
-
-
84871251698
-
Revised international chapel hill consensus conference nomenclature of vasculitides
-
Jennette JC, Falk RJ, Bacon PA et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65 : 1 - 11.
-
(2012)
Arthritis Rheum
, vol.65
, pp. 1-11
-
-
Jennette, J.C.1
Falk, R.J.2
Bacon, P.A.3
-
4
-
-
84926615364
-
Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis
-
Watts RA, Mahr A, Mohammad AJ et al. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant 2015; 30( Suppl 1): i14-i22.
-
(2015)
Nephrol Dial Transplant
, vol.30
, pp. i14-i22
-
-
Watts, R.A.1
Mahr, A.2
Mohammad, A.J.3
-
5
-
-
84918575913
-
Damage in the anca-associated vasculitides: Long-term data from the European vasculitis study group (EUVAS) therapeutic trials
-
Robson J, Doll H, Suppiah R et al. Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis 2015; 74 : 177 - 84.
-
(2015)
Ann Rheum Dis
, vol.74
, pp. 177-184
-
-
Robson, J.1
Doll, H.2
Suppiah, R.3
-
6
-
-
72249087511
-
Modification and validation of the birmingham vasculitis activity score (version 3)
-
Mukhtyar C, Lee R, Brown D et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009; 68 : 1827 - 32.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 1827-1832
-
-
Mukhtyar, C.1
Lee, R.2
Brown, D.3
-
7
-
-
84976590642
-
Can an increase in anti-neutrophil cytoplasmic autoantibody titer predict relapses in anti-neutrophil cytoplasmic antibody associated vasculitis?
-
Koh JH, Kemna MJ, Cohen Tervaert JW, Kim WU. Can an increase in anti-neutrophil cytoplasmic autoantibody titer predict relapses in anti-neutrophil cytoplasmic antibody associated vasculitis? Arthritis Rheum 2016; 68; 1571 - 3.
-
(2016)
Arthritis Rheum
, vol.68
, pp. 1571-1573
-
-
Koh, J.H.1
Kemna, M.J.2
Cohen, T.J.W.3
Kim, W.U.4
-
8
-
-
34248218149
-
EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: Focus on anti neutrophil cytoplasm antibody associated vasculitis
-
Hellmich B, Flossmann O, Gross WL et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti neutrophil cytoplasm antibody associated vasculitis. Ann Rheum Dis 2007; 66 : 605 - 17.
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 605-617
-
-
Hellmich, B.1
Flossmann, O.2
Gross, W.L.3
-
9
-
-
0038122889
-
Arandomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies
-
Jayne D, Rasmussen N, Andrassy K et al. Arandomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349 : 36 - 44.
-
(2003)
N Engl J Med
, vol.349
, pp. 36-44
-
-
Jayne, D.1
Rasmussen, N.2
Andrassy, K.3
-
10
-
-
84860920482
-
Pulse versus daily oral cyclophosphamide for induction of remission in ANCAassociated vasculitis: Long-term follow-up
-
Harper L, Morgan MD, Walsh M et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCAassociated vasculitis: long-term follow-up. Ann Rheum Dis 2012; 71 : 955 - 60.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 955-960
-
-
Harper, L.1
Morgan, M.D.2
Walsh, M.3
-
11
-
-
84928957372
-
BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis
-
Ntatsaki E, Carruthers D, Chakravarty K et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis . Rheumatology 2014; 53 : 2306 - 9.
-
(2014)
Rheumatology
, vol.53
, pp. 2306-2309
-
-
Ntatsaki, E.1
Carruthers, D.2
Chakravarty, K.3
-
12
-
-
84978946297
-
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
-
Yates M, Watts RA, Bajema IM et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016; 75 : 1583 - 94.
-
(2016)
Ann Rheum Dis
, vol.75
, pp. 1583-1594
-
-
Yates, M.1
Watts, R.A.2
Bajema, I.M.3
-
13
-
-
77954651554
-
Rituximab versus cyclophosphamide for ANCA-associated vasculitis
-
Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363 : 221 - 32.
-
(2010)
N Engl J Med
, vol.363
, pp. 221-232
-
-
Stone, J.H.1
Merkel, P.A.2
Spiera, R.3
-
14
-
-
77954632414
-
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis
-
Jones RB, Tervaert JW, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363 : 211 - 20.
-
(2010)
N Engl J Med
, vol.363
, pp. 211-220
-
-
Jones, R.B.1
Tervaert, J.W.2
Hauser, T.3
-
15
-
-
84954288948
-
Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)- Associated vasculitis based on ANCA type
-
Unizony S, Villarreal M, Miloslavsky EM et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)- Associated vasculitis based on ANCA type. Ann Rheum Dis 2016; 75 : 1166 - 9.
-
(2016)
Ann Rheum Dis
, vol.75
, pp. 1166-1169
-
-
Unizony, S.1
Villarreal, M.2
Miloslavsky, E.M.3
-
16
-
-
67650094918
-
A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis
-
Jones RB, Ferraro AJ, Chaudhry AN et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60 : 2156 - 68.
-
(2009)
Arthritis Rheum
, vol.60
, pp. 2156-2168
-
-
Jones, R.B.1
Ferraro, A.J.2
Chaudhry, A.N.3
-
17
-
-
23644455521
-
Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis
-
De Groot K, Rasmussen N, Bacon PA et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52 : 2461 - 9.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 2461-2469
-
-
De Groot, K.1
Rasmussen, N.2
Bacon, P.A.3
-
18
-
-
84868087895
-
Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibodyassociated vasculitis
-
Smith RM, Jones RB, Guerry MJ et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum 2012; 64 : 3760 - 9.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 3760-3769
-
-
Smith, R.M.1
Jones, R.B.2
Guerry, M.J.3
-
19
-
-
84908576790
-
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis
-
Guillevin L, Pagnoux C, Karras A et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371 : 1771 - 80.
-
(2014)
N Engl J Med
, vol.371
, pp. 1771-1780
-
-
Guillevin, L.1
Pagnoux, C.2
Karras, A.3
-
20
-
-
84904917293
-
The informational needs of patients with ANCA-associated vasculitis-development of an informational needs questionnaire
-
Mooney J, Spalding N, Poland F et al. The informational needs of patients with ANCA-associated vasculitis-development of an informational needs questionnaire. Rheumatology 2014; 53 : 1414 - 21.
-
(2014)
Rheumatology
, vol.53
, pp. 1414-1421
-
-
Mooney, J.1
Spalding, N.2
Poland, F.3
|